PROTHENA CORPORATION PUBLIC LIMITED COMPANY Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions of $619.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions · last filed 2026-02-27
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2025 was $619.00K, a 383.59% increase from fiscal 2024.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2024 was $128.00K, a 77.35% decline from fiscal 2023.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2023 was $565.00K.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month |
|---|---|
| 2025-12-31 | $619.00K 10-K · filed 2026-02-27 |
| 2024-12-31 | $128.00K 10-K · filed 2026-02-27 |
| 2023-12-31 | $565.00K 10-K · filed 2025-02-27 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-22 |
| 2021-12-31 | $265.00K 10-K · filed 2023-02-28 |
| 2020-12-31 | $176.00K 10-K · filed 2022-02-25 |
| 2019-12-31 | $625.00K 10-K · filed 2021-02-26 |
| 2018-12-31 | $34.00K 10-K · filed 2020-03-03 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-15 |
| 2016-12-31 | $1.00K 10-K · filed 2018-02-26 |
| 2015-12-31 | $0.00 10-K · filed 2017-02-27 |
| 2014-12-31 | $350.00K 10-K · filed 2016-02-25 |
| 2013-12-31 | $0.00 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |